Summary of Key Points Core Viewpoint - The company, Hunan Jiutian Pharmaceutical Co., Ltd., is changing the use of raised funds from a new drug research project to a new antibacterial peptide drug research project due to market environment changes and actual development needs [1][9]. Group 1: Fundraising Overview - The company raised a total of RMB 270 million through the issuance of convertible bonds, with a net amount of RMB 262.62 million transferred to a special account [1]. - As of June 30, 2025, the company has invested RMB 176.04 million in fundraising projects, leaving a remaining balance of RMB 98.09 million [2][3]. Group 2: Change in Fund Usage - The original project, which involved the development of improved new drugs, has seen an investment of RMB 19.69 million, with RMB 98.09 million remaining uninvested [4][5]. - The company plans to redirect the remaining funds entirely to the new antibacterial peptide drug research project, which will account for 36.33% of the total raised funds [3][4]. Group 3: Project Details - The new project involves the development of antibacterial peptides, which are expected to address the growing issue of antibiotic resistance and have potential applications in treating various infections [6][7]. - The project is anticipated to enhance the company's product offerings and support future business growth [6][9]. Group 4: Approval Process - The change in fundraising usage has been approved by the company's board and requires shareholder approval [9][10]. - The adjustment aligns with regulatory requirements and does not harm shareholder interests [10].